Retatrutide may not be approved for general prescription use in all locations and may only be available through clinical research settings
Dual agonists that activate both GLP-1 and GIP receptors have been shown to provide more pronounced weight loss, better glycemic control, and better metabolic outcomes compared to GLP-1 RAs alone
Outcomes suggest semaglutide produced poorer outcomes, with a significantly elevated incidence of all-cause mortality (Risk Ratio [RR]: 1.56), AMI (RR: 1.21), ischemic stroke (RR: 1.64, p=0.024) and readmission (RR: 1.15) compared to tirzepatide
Theres no guarantee that tranexamic acid will work for you - and generally it has been thought of as a last resort of sorts for treating the melasma cases that are resistant to laser therapy and other medications, because it does have potential side effects, whereas laser therapy does not
Some required hospitalization
The third ingredient is a progestogen to protect the endometrium